Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1757-1767

  Jeselsohn, Rinath ^a,b   Yelensky, Roman ^d   Buchwalter, Gilles ^a,b   Frampton, Garrett ^d   Meric Bernstam, Funda ^e   Gonzalez Angulo, Ana Maria ^e   Ferrer Lozano, Jaime ^f   Perez Fidalgo, Jose A ^f   Cristofanilli, Massimo ^g   Goḿez, Henry ^h   Arteaga, Carlos L ⁱ   Giltnane, Jennifer ⁱ   Balko, Justin M ⁱ   Cronin, Maureen T ^d   Jarosz, Mirna ^d   Sun, James ^d   Hawryluk, Matthew ^d   Lipson, Doron ^d   Otto, Geoff ^d   Ross, Jeffrey S ^d   Dvir, Addie ^j   Soussan Gutman, Lior ^j   Wolf, Ido ^k   Rubinek, Tamar ^k   Gilmore, Lauren ^c   Schnitt, Stuart ^c   Come, Steven E ^c   Pusztai, Lajos ^l   Stephens, Philip ^d   Brown, Myles ^a   Miller, Vincent A ^d   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d FOUNDATION MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

ⁱ VANDERBILT INGRAM CANCER CENTER   (United States)

^j TEVA PHARMACEUTICALS   (Israel)

^k TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^l YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; DASATINIB; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; SELUMETINIB;

ARTICLE; BREAST METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CODON; CONTROLLED STUDY; DISEASE COURSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATION RATE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DOMAIN; SOMATIC MUTATION; TUMOR GENE; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; MCF 7 CELL LINE; MUTATION; NEOPLASM; PATHOLOGY;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MCF-7 CELLS; MUTATION; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT;

EID: 84898717745     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2332     Document Type: Article

References (45)

1. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Ef ficacy and Tolerability study. J Clin Oncol 2000;18:3741-57.
2. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3751-67.
3. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. (Pubitemid 34694019)
4. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:231-47.
5. Garcia-Becerra R, Santos N, Diaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 2012;14:101-45.
6. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:351-61.
7. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 1998;95:2921-5.
8. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:531-40.
9. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000;6:701-6.
10. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endoc Rev 2004;25:861-98.
11. Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 1996;10:1381-98.
12. Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 1997;36:14891-905.
13. White R, Sjoberg M, Kalkhoven E, Parker MG. Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine. EMBO J 1997;16:1421-35.
14. Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 1995;87:441-51.
15. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:351-60.
16. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:401-4.
17. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486:401-9.
18. Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994;54:341-53.
19. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997;57:1241-9.
20. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1751-60.
21. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25:2071-9.
22. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011;43:491-8.
23. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011;39:D941-50.
24. Compeau PE, Pevzner PA, Tesler G. How to apply de Bruijn graphs to genome assembly. Nat Biotechnol 2011;29:981-91.
25. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012;30:411-21.
26. VanLoo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A 2010;107:16911-5.
27. Yau C, Mouradov D, Jorissen RN, Colella S, Mirza G, Steers G, et al. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol 2010;11:R92.
28. Meric-Bernstam F, Frampton G, Ferrer-Lozano J, Yelensky R, Palmer GA, Cronin MT, et al. Cancer gene profile of metastatic breast cancer. J Clin Oncology 2012;30 (suppl; abstract 1015).
29. Swaby RF, Jordan VC. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer 2008;8:121-33.
30. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009;302:771-80.
31. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013;4:1111-30.
32. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013;45:1439-45.
33. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013;45:1446-51.
34. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, et al. D538G mutation in estrogen receptoralpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 2013;73:6851-64.
35. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
36. Baselga J, Campone M, Piccart M, Burris HAIII, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:521-9.
37. Pearce ST, Liu H, Jordan VC. Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem 2003;278:7631-8.
38. Lazennec G, Ediger TR, Petz LN, Nardulli AM, Katzenellenbogen BS. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes. Mol Endoc 1997;11:1371-86.
39. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4591-600.
40. Wolf DM, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 1994;31:121-38.
41. Wolf DM, Jordan VC. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat 1994;31:111-27.
42. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, et al. Estrogen receptor alpha (ESR1) gene ampli fication is frequent in breast cancer. Nat Genet 2007;39:651-60.
43. Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, Yamamoto Y, et al. Estrogen receptor alpha gene ESR1 ampli fication may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci 2009;100:1011-7.
44. Adelaide J, Finetti P, Charafe-Jauffret E, Wicinski J, Jacquemier J, Sotiriou C, et al. Absence of ESR1 amplification in a series of breast cancers. Int J Cancer 2008;123:2971-2.
45. Brown LA, Hoog J, Chin SF, Tao Y, Zayed AA, Chin K, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008;40:801-7.